Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated the effects of sodium cantharidate (SC), either as monotherapy and in combination with the EGFR inhibitor erlotinib, on STAT3 activation and osteosarcoma cell growth.
|
31422383 |
2019 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Unlike EGFR or PDGFR, IGF1Rβ levels correlated with CYR61 and N-cadherin levels, and with the aggressiveness of osteosarcoma and overall survival.
|
30642298 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulation or the constitutive activation of epidermal growth factor receptor (EGFR) is a hallmark of osteosarcoma.
|
31404298 |
2019 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we summarized the roles and expression of ErbB family in OS and the current development of ErbB-targeted therapeutic strategies including chemotherapies and immunotherapies for OS treatment.
|
30353245 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the sensitivity of only a few tumors to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can be explained by the presence of EGFR tyrosine kinase (TK) domain mutations, there is a need to elucidate mechanisms of resistance to EGFR-targeted therapies in OS that do not harbor TK sensitizing mutations to develop new strategies to circumvent resistance to EGFR inhibitors.
|
31138318 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: The identification of genetic driver alterations led to the selection of patients who are most likely to benefit from epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) and rat osteosarcoma (ROS-1) tyrosine kinase inhibitors; on the other hand, in the absence of oncogenic alterations, platinum-based doublet chemotherapy regimens were the cornerstone of treatment.
|
30640563 |
2019 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventeen (28.33%), 15 (25.00%) and 15 (25.00%) osteosarcoma specimens presented with amplification of EGFR, ErbB3 and ErbB4 gene, respectively, which were significantly higher compared with non-neoplastic bone tissues.
|
31663373 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-337-5p participates in the development and progression of osteosarcoma via ERBB, MAPK and VEGF pathways.
|
30229817 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
As epidermal growth factor receptor (EGFR) positively correlates with TNM (tumor-node-metastasis) stage in osteosarcoma, EGFR may play an important role in its progression.
|
29751634 |
2018 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, we transfected EGFR and EGFR DEL (mutation with miR-141 binding site) in osteosarcoma cells, and detected the effects of miR-141 on cell proliferation, apoptosis, migration and related proteins.
|
30104888 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical studies using human OS xenografts revealed that only tumors expressing both EGFR and c-Fos responded to anti-EGFR therapy demonstrating that c-Fos can be considered as a novel biomarker predicting response to anti-EGFR treatment in OS patients.
|
30361264 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Physakengose G induces apoptosis via EGFR/mTOR signaling and inhibits autophagic flux in human osteosarcoma cells.
|
29655686 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclic Guanosine Monophosphate (cGMP)-Dependent Protein Kinase II Blocks Epidermal Growth Factor (EGF)/Epidermal Growth Factor Receptor (EGFR)-Induced Biological Effects on Osteosarcoma Cells.
|
29617357 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hereby constructed sali-entrapped lipid-polymer nanoparticles labeled with CD133 and EGFR aptamers (CESP) to target both osteosarcoma cells and CSCs.
|
29898423 |
2018 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TFs identified in the EGFR promoter may function in the progression of OS.
|
29435005 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the interaction of EGFR aptamers and EGFR is a potential approach to promote the effective delivery of salinomycin to osteosarcoma.
|
29399118 |
2018 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the role of EGFR and HER-2 expression in osteosarcoma survival remains controversial and no previous study has simultaneously investigated the association of the expression of all the four HER family members with the prognostic significance of osteosarcoma.
|
30008917 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> functional assays demonstrated that targeting IGF-IR and EGFR didn't affect osteosarcoma cell viability, but inhibited ligand-activated intracellular signaling and cell migratory capacity.
|
28744395 |
2017 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Xenografted SPC24 knockdown osteosarcoma cells showed reduced tumor growth in nude mice with decreased EGFR and phospho-ERK levels and increased E-cadherin levels.
|
29285250 |
2017 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in osteosarcoma.
|
27830833 |
2016 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined that AREG increases the expression of intercellular adhesion molecule-1 (ICAM-1) through PI3K/Akt signaling pathway via its interaction with the epidermal growth factor receptor, thus resulting in the enhanced cell migration of osteosarcoma.
|
26503469 |
2015 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the gene expression levels of three known targets in advanced gastric cancer, epidermal growth factor receptor (EGFR), human epidermal growth factor 2 (HER2), and N-methyl-N-nitrosoguanidine human osteosarcoma transforming gene (MET), using the nCounter® assay (NanoString Technologies, Seattle, WA, USA) and compared these results with protein overexpression, detected by immunohistochemistry, to evaluate the performance of this new technology.
|
25445175 |
2015 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functionality of EGFR in osteosarcoma cells was proven by EGF-mediated activation of both MAPK and PI3K/AKT pathway (determined by phosphorylation of ERK1/2, AKT, S6, and GSK3β).
|
26526352 |
2015 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, PKC can be activated by several receptor tyrosine kinases implicated in osteosarcoma, including the ERBB family (EGFR, Her-2 and Her-4 in osteosarcoma), IGF1R, FGF, and others.
|
24924170 |
2014 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
GAK appears to be essential for cell death because co-administration of gefitinib and luteolin to EGFR-deficient U2OS osteosarcoma cells also had a greater effect on cell viability than administration of either compound alone.
|
24971999 |
2014 |